Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
onset 4: FIAsp in CSII
NCT01999322Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2013
- Primary completion
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Microscopically Confirmed Episodes of Infusion Set Occlusions at 6 weeks. Started Nov 2013; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01999322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999322.